Main Conference: 29-30 April 2027 | Hamburg, Germany
Cell Culture & Upstream Processing
Maximizing Volumetric Productivity, Process Robustness, and Upstream Yield
Future-proof your bioreactor operations and scale-up strategies.
The Cell Culture & Upstream Processing Track at BioProcess International Europe 2027 brings together leading bioprocess engineers, upstream directors, and fermentation experts to accelerate process intensification, optimise feed media, and implement dynamic closed-loop control from benchtop to commercial scale.
Go Beyond Theory in Upstream Manufacturing
BioProcess International Europe 2027 returns to Hamburg with a 2-day program designed to address the urgent macroeconomic pressures facing biopharma manufacturing, including patent cliffs, market competition, and the race to lower cost of goods (COGs).
As commercial pipelines demand higher volumetric productivity and tighter control over Critical Quality Attributes (CQAs), upstream development is shifting from traditional empirical fed-batch approaches to intensified, automated, and digitally steered bioprocessing. This track delivers practical case studies and technical breakthroughs in N-1 perfusion, high-density cell culture, microscale scale-down models, and raw material variability management. Discover how leading teams are leveraging cross-industry precision fermentation innovations, deploying non-invasive in-line PAT, and integrating active AI digital twins to automate bioreactor steering and de-risk global tech transfer.
Track Themes: A Blueprint for Upstream Excellence
Feed Optimisation & Raw Materials
Designing Media for Downstream Simplification: Formulate upstream feeds that mitigate raw-material batch variability while intentionally simplifying downstream purification steps to drastically reduce overall COGs.
High-Titer Fed-Batch Systems: Balance cellular growth with protein production by optimising trace metal concentrations, media solubility, and dynamic feed schedules.
Process Mapping & Scale-Down Predictive Models
High-Throughput Microscale Bioreactors: Deploy micro-scale arrays to run automated multi-variable experiments in parallel while compressing preclinical timelines.
Evaluating Long-Term Clonal Performance: Audit scale-down models to accurately predict which clones maintain growth behaviour, productivity, and product quality after prolonged culture and commercial transfer.
Upstream Intensification & Perfusion Operations
Operationalising High-Density Culture: Address mechanical and operational hurdles in perfusion set-ups, including fluid handling, cell retention systems, and facility-fit considerations when transitioning from fed-batch.
Design-for-Conjugation: Utilise targeted peptide media additives to steer microheterogeneity and post-translational quality during bioreactor runs, locking in consistent Drug-to-Antibody Ratios (DAR) for complex formats.
Real-Time PAT & In-Line Sensors
In-Line Sensors & Optical Flow Cells: Deploy non-invasive FT-IR flow cells and real-time metabolite sensors directly into fluid paths to automate feed adjustments and satisfy Quality by Design (QbD) frameworks.
In-Line Imaging & Digital Twins: Utilise computer vision to monitor cell viability and detect apoptotic cells automatically, eliminating the need for manual off-line sampling.
Explore the full Cell Culture & Upstream Processing Agenda
Cell Culture & Upstream Processing: Q&A & Expert Insights
How are AI and digital twins applied to upstream bioreactors?
Discussions focus on verified case studies where active digital twins use real-time optical/spectroscopic sensor metrics to dynamically steer bioreactor parameters. Attendees will learn how to validate non-deterministic predictive algorithms under GAMP 5 and EU AI Act regulatory guidelines.
What strategies are used to scale up bioprocesses to 20,000L?
Scaling to 20,000L requires robust strategies to overcome differences in mixing and oxygen transfer. Approaches include using Computational Fluid Dynamics (CFD) and "evolutionary AI" to design lab-scale bioreactors that physically mimic large-scale hydrodynamic conditions. This enables predictive scale-down testing, allowing engineers to identify risks like nutrient gradients or shear stress before expensive pilot trials.
How can in silico modelling optimise cell culture media?
Hybrid modelling combines data-driven insights with mechanistic equations to optimise fed-batch media formulations in silico. This approach helps define the optimal balance of amino acids and nutrients to maximise titre and manage metabolites (like lactate), reducing the need for extensive wet-lab experiments and accelerating process development.
How do you overcome clarification bottlenecks in high-density cell cultures?
Intensified upstream processes often produce high-titre, high-solids harvests that challenge traditional clarification. Next-generation strategies include novel filtration and centrifugation technologies designed specifically for high-density harvests, ensuring efficient primary recovery without compromising yield or fouling downstream filters.
What are the advantages of transitioning AAV production to suspension culture?
Moving from adherent systems to high-density suspension processes is critical for commercial AAV manufacturing. Suspension cultures are more scalable and robust, allowing for better control over triple-transfection efficiency and viral particle yield. Optimisation strategies often involve perfusion to improve the full-to-empty capsid ratio.
How does the 2027 Upstream track help cut biomanufacturing COGs?
The 2027 agenda focuses on using upstream feed strategies to directly simplify downstream purification, cutting raw material costs and buffer footprints. Additionally, cross-industry case studies explore applying low-shear, gas-exchange controls from precision fermentation into mammalian systems to reduce high-volume vessel operating costs.